Background: As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients.
introduction Extra-pulmonary neuroendocrine carcinomas (NEC) are most often found in the gastrointestinal (GI) tract [1, 2] . In up to 30% of cases, no primary tumor localization can be identified [3] . These tumors were previously defined as poorly differentiated endocrine carcinoma [4] . In the 2010 World Health Organization (WHO) GI classification, the tumors are still grouped as WHO G3 (Ki-67 > 20%), but the nomenclature has been changed to NEC [5] . Gastrointestinal NEC (GI-NEC) account for 35-55% of all extra-pulmonary NEC, and are mainly located in the esophagus, stomach, pancreas and colon [6] [7] [8] . GI-NEC encompass two histopathological entities: small-cell NEC (SCNEC) and large-cell NEC (LCNEC) [5, 9] . It is not clear whether SCNEC should be treated differently from LCNEC. Clinical data describing NEC are spare partly because many cases have been incorporated in the general neuroendocrine tumor group, and partly because many cases are frequently misdiagnosed as poorly differentiated adenocarcinoma. GI-NEC have a high proliferation rate with a Ki-67 index >20% by definition, but usually higher (>75%) [10] . They are characterized by molecular markers of neuroendocrine differentiation; synaptophysin is usually positive while chromogranin A (CgA) is less frequently present. Positive CgA staining indicates a more mature tumor, and the presence of both synaptophysin and CgA is considered to be a good prognostic sign [11, 12] . Guidelines state that GI-NEC usually have normal serum CgA, that hormonal symptoms are rare and somatostatin receptor scintigraphy (SRS) is negative [13] .
Most GI-NEC are metastatic at the time of diagnosis. In the surveillance epidemiology and end results (SEER) database, distant disease at diagnosis was present in 62% of patients with colorectal NEC [14] . The median survival in untreated patients is usually 4-6 months. Among 94 GI-NEC patients in the National Cancer registry of Spain, 67% had metastatic disease with a median survival of 1.7 months [15] . Advanced disease is usually treated with systemic chemotherapy as NEC do not respond to the treatment used in other neuroendocrine tumors [16, 17] . In devising treatment strategies for extra-pulmonary NEC, many authors refer to the extensive literature on highgrade NEC of the lung [2, 10] . Several series have questioned the rationale for this and pointed out many differences between pulmonary small-cell carcinoma and SCNEC [6, 18] . Guidelines for treating extra-pulmonary NEC advocate the use of platinum-based chemotherapy combined with etoposide [1, 13, 19] , although only few and small first-line chemotherapy studies have been reported [20, 21] . Not much is known about the possible benefit from second-line treatment, although we recently reported promising results of temozolomide-based chemotherapy [12] .
There is a lack of epidemiological, clinical and treatment data for these patients and little is known of prognostic and predictive factors. The treatment of GI-NEC has been quite similar in the Nordic countries concerning first-line therapy since 2000. With the aim of identifying predictive and prognostic factors in advanced GI-NEC, we retrospectively collected epidemiological, tumor and treatment data on patients diagnosed in Nordic centers during 2000-2009. patients and methods NEC patients were identified from neuroendocrine registries, chemotherapy registries, hospital charts coding and pathology coding at 12 Nordic University Hospitals. The inclusion criteria were: histopathological confirmed diagnosis of NEC (Ki-67 > 20%) with a GI primary or an unknown primary (CUP) predominantly with GI metastases [21] and metastatic or not curable locally advanced disease diagnosed between January 2000 and April 2009. Data regarding epidemiology, biochemistry, tumor proliferation index, treatment and survival were registered retrospectively. Tumor morphology was based on pathology reports and classified into small-cell versus non-small-cell (no mention of small-cell morphology present in the report or large-cell morphology stated). The response rates were evaluated according to RECIST 1.0 criteria based on radiological reports. Cut-off levels for biochemical results were used as those shown to be prognostic in advanced colorectal cancer studies [22] . The ethics committees in Norway, Sweden, Denmark and Finland approved the study.
statistics
The statistical analysis was done by PASW 18. We used methods of descriptive statistics. Comparisons of groups were carried out by χ2-test for categorical and Wilcoxon-or Student's t-test for continuous variables. This is specified in the result tables. The best cut-off value for Ki-67 regarding the response rate was computed using a receiver operating characteristic (ROC) curve analysis (response = CR/PR versus no response = SD/PD) for 42 randomly selected chemotherapy treated patients. All analyses using the dichotomized Ki-67 were done including only the remaining patients. The survival analysis was done using the Kaplan-Meier-analysis and Cox regressions for patient receiving chemotherapy. The multivariate Cox analysis was done for a fully adjusted model as well as unadjusted models for all predictors in the model. From these computations, we derived a final model containing only the relevant variables taking into account significance information from the other models as well as the covariance structure of the predictors. The general significance level was set to 0.05. In the regression model, 0.01 was used to weaken multiple effects.
results

patient characteristics
Altogether, 305 patients were included in the study and of these 301 had metastatic disease and 4 had locally advanced unresectable disease. Main patient characteristics are presented in Table 1 . Far more patients were found in the period 2005-2009 compared with 2000-2004. Three percent had hormone related symptoms at diagnosis. Urine-5-hydroxyindoleacetic acid (U-5HIAA) was measured in 94 patients (majority with relatively low Ki-67) and elevated in 24 patients, while CgA was measured in 188 patients and increased in two-third of them. Thirty-six patients (12%) had prior cancer disease. A high uptake on SRS was more often found in primary pancreatic tumors (46%) than in primary from other locations (0-25%) (P = 0.001, analyzed by group), but SRS was less frequently carried out in patients with a high Ki-67. SCNEC had more often than non-SCNEC a positive SRS (45% versus 32% P = 0.044). No differences in smoking habits were found between SCNEC and non-SCNEC.
histopathology Small-cell morphology was specified in the pathology reports of 115 patients, and 148 patients had non-small-cell morphology. Small-cell morphology was frequently present in primary esophageal (75%) and rectal tumors (65%), whereas non-small-cell morphology was more often present in colonic (70%) primaries. The Ki-67 index was usually >55% in primary tumors from the esophagus (67% of tumors), colon (70%) and rectum (80%), whereas in primary tumors from the pancreas only 30% had a Ki-67 ≥ 55%. Regarding the Ki-67 level, we found no differences between SCNEC and non-SCNEC. There was no significant difference in the intensity of CgA staining when comparing SCNEC with non-SCNEC (52% versus 45%, P = 0.2). No correlation was found between the CgA staining intensity and the location of the primary tumor.
treatment
Palliative chemotherapy was given to 252 patients, whereas 53 patients were treated with best supportive care (BSC). Patients treated with BSC were older, had a worse performance status (PS), less positive SRS, less intense CgA staining and more often elevated white blood cell count (WBC) and C-reactive protein (CRP) levels (Table 1) . Primary colon tumors were often resected (80%), whereas this was rarely the case for esophageal (22%), gastric (31%), pancreatic (15%) and rectal (28%) tumors. Tumors with small-cell morphology were less often resected (19% versus 34%, P = 0.012).
First-line chemotherapy was given with cisplatin/etoposide (n = 129), carboplatin/etoposide (n = 67), carboplatin/ etoposide/vincristine (n = 28) or other drugs (n = 28). The use of carboplatin or cisplatin was mainly due to different center policy. The median number of chemotherapy cycles was four (range 1-15), 25% of the patients were treated with only one to two cycles. Reintroduction of cisplatin/carboplatin and etoposide after a treatment break (usually for at least 3 months) was given to 29 patients. Second-line chemotherapy was administered to 100 patients; of these 35 received temozolomide-based chemotherapy and 20 taxotere-based chemotherapy. Third-line chemotherapy was given to 31 patients.
response evaluation and ROC analysis
Response rate after first-line chemotherapy was 31%; another 33% had disease stabilization (SD) whereas 36% had disease progression (PD) ( Table 2 ). Response evaluation was missing for 23 patients (9%). The best cut-off value concerning response rate for Ki-67 by ROC-analysis was 55% (supplementary Figure S1 , available at Annals of Oncology online and supplementary Table S1 , available at Annals of Oncology online). Half of the patients had a Ki-67 level <55%. Response rate was lower (15% versus 42%) when Ki-67 was <55% (P < 0.001). No differences were seen in the response rate regarding tumor morphology or presence of positive CgA staining. Patients with PS 2 had a higher percentage of immediate disease progression compared with PS 0 (61% versus 26%). The response rates did not differ among the various platinum chemotherapy schedules (Table 3) . Reintroduction of cisplatin/carboplatin and etoposide after a treatment break resulted in a response rate of 15% and 27% achieved SD (26 assessable patients). The response rate after second-line chemotherapy for 84 assessable patients was 18%, 2 complete responses (CR) and 13 partial responses (PR), 33% SD and 49% PD. The response rates after third-line chemotherapy for 29 assessable patients were 7% (2 PR), 34% SD and 59% PD.
survival
The median survival in patients not receiving chemotherapy was 1 month (95% confidence interval (CI) 0.3-1.8 m) and for patients receiving chemotherapy 11 months (95% CI 9.4-12.6 m). Two-year survival was 14% and 3-year survival was 9.5% for chemotherapy-treated patients. Several baseline factors were substantially related to survival for chemotherapy-treated patients (Table 2) . Patients with Ki-67 < 55% had a significantly longer survival compared with patients with higher Ki-67 levels (14 versus 10 m, P < 0.05) ( Oncology online). Thirty months after chemotherapy initiation, 23% of patients with a Ki-67 <55% were alive compared with only 7% when Ki-67 ≥ 55% (P < 0.001). Patients with PS2 had a poor survival after chemotherapy; 63% died within 6 months and 3% were alive at 12 months (Table 2, Figure 1B ). However, for those PS2 patients with a PR after chemotherapy (25%), progression-free survival (PFS) was 5 months and median survival 11 months. Patients with primary colon tumors had a significantly shorter median survival compared with patients with pancreatic primary tumors (8 versus 15 m, Figure 1C ). No differences in survival were seen concerning histopathological morphology or intensity of CgA staining. Survival did not differ between patients treated with the different platinum chemotherapy schedules (Table 3 , Figure 1D ). The median survival was 15 months in patients who had either PR (95% CI 11.0-19.0 m) or SD (95% CI 12.4-17.5 m) as the best response Significant differences within the group in PFS (P = 0.015) and survival (P = 0.01).
b Main metastatic load in GI. c Significant differences in RR (P < 0.001) and survival (P = 0.001). d
Significant differences in PFS (P = 0.021). e Significant differences within the group in RR (P = 0.012), PFS (P < 0.001) and survival (P < 0.001). CUP, cancer of unknown primary; CR, complete response; GI, gastrointestinal; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. Table S2 , available at Annals of Oncology online). The results of the Cox regression on prognostic factors for survival are shown in Table 4 and supplementary Table S3 , available at Annals of 
Annals of Oncology original articles
Oncology online. PS, location of primary tumor and blood levels of platelets and LDH were the strongest prognostic factors for survival in multivariate analyses. In the multivariate models, platelets and LDH are representatives for two clusters of strongly correlated variables shown in supplementary Table S2 , available at Annals of Oncology online. Note that Ki-67 is significant in the unadjusted model but neither in the full nor in the final model. This is caused by the strong association between Ki-67 and the primary tumor (P < 0.001). For the 36 patients with PS 0 and normal levels of platelets and LDH, the median survival was 26 months and 47% were alive at 30 months. discussion This is, to our knowledge, the largest cohort of advanced GI-NEC patients ever reported. Although the study is retrospective with its limitations, novel data on this disease are highly requested, as the incidence is increasing and the treatment of these patients remain a challenge for clinicians. Advanced GI-NEC is an aggressive disease where rapid referral to an oncologist is mandatory, some advocate referral within a week. Patients should be referred for possible treatment before the PS deteriorates to the extent that the patient is no longer fit to receive chemotherapy. In accordance, the PS in our study was the strongest independent prognostic factor for survival. The exceedingly low median survival for our patients not receiving chemotherapy may be biased by late referral of the patient and more advanced disease stages (as worse PS and WBC/CRP may indicate) or conditions such as age that did not allow chemotherapy treatment. A relevant clinical question is whether GI-NEC patients with poor PS will benefit from a potentially toxic platinum-based treatment. Chemotherapy will not benefit all patients and could even hasten their outcome. In our PS2 patients, the response rate was 23% and 16% had SD, but as many as 61% had no benefit from treatment. The median survival for PS2 patients was only 5 months and only 3% were alive at 12 months. However, in PS2 patients who achieved a PR after chemotherapy, PFS and median survival were 5 and 11 months respectively. In our study, the primary tumors were most frequently found in the pancreas and large bowel, whereas in a previous study in 64 GI-NEC patients the most common locations were esophagus and large bowel [23] . We found a median survival of 8 months in primary colon tumors, significantly shorter than in patients with primary pancreatic tumors (15 months). Patients with a primary pancreatic tumor had more often SRS positive tumors and more often a Ki-67 <55%, and may thus constitute a specific subgroup within GI-NEC with a better prognosis. In a recent study, the median survival for 32 advanced pancreatic NEC was 21 months [24] , quite similar to our results. It has been debated whether NEC with small-cell morphology should be treated differently from non-small-cell tumors. Previously, no significant differences in survival based on histological subtypes have been found [9, 25] . In our study, there were no differences in the response rate and survival according to subtype morphology, and the clinical relevance of this morphological classification is uncertain. However, our patients have not been specifically re-classified according to the new WHO 2010 criteria. The importance of the proliferation rate in neuroendocrine tumors is reflected in the tumor classification, and treatment is often based on the Ki-67 level also in highly differentiated tumors [26] . The importance of Ki-67 level has also been shown in other tumors, e.g. as a prognostic factor in breast cancer patients and predictive for the benefit of adjuvant systemic therapy [27] . In our study, we found that tumors with Ki-67 <55% were less responsive to platinum-based chemotherapy, but had a significant longer survival and may thus constitute a different disease entity. Platinum-based chemotherapy may furthermore not be the optimal chemotherapy schedule when Ki-67 < 55%. When temozolomide-based chemotherapy was given to GI-NEC after first-line platinum-based chemotherapy, patients with Ki-67 < 60% had a better response [12] . Although our study by both ROC analyses and Ki-67 10% percentiles support a cut-off around 50% concerning the response rate and survival, this should be interpreted with some cautiousness. Ki-67 was assessed by many different pathologists from different countries, and analysis may be biased by the methodology and experience of the pathologist as well as issues of Ki-67 heterogeneity. In our study, the median number of chemotherapy courses was 4; the response rate was 31% (2% CR, 29% PR) and the disease control rate 64% with a median survival of 11 months. Long-time survival was rare and only 9.5% were alive after 3 years. In the study by Moertel et al., including 18 predominantly GI-NEC patients, the median number of courses was 5, 67% had objective tumor regression and median survival was 19 months [20] . Mitry et al. included 41 poorly differentiated NEC, 27 GI-NEC or CUP with predominantly GI metastases [21] . The median number of courses was 4, response rate 42% (10% CR, 32% PR), 34% achieved SD and median survival was 15 months. Our data suggest that response the rates and survival of GI-NEC patients might be lower than previously reported. In a colorectal NEC original articles Annals of Oncology database, the median survival was 10 months with 1-year, 2-year and 3-year survival rates of 46%, 26% and 13%, respectively [25] . In a series of 53 cases of gallbladder NEC, those with disseminated disease had a median survival of 8 months after treatment with combination chemotherapy with 1-and 2-year survival rates of 28% and 0%, respectively [28] .
In the SEER database of colorectal NEC, 5-year survival was 6% in patients with metastases [15] . Based on two first-line chemotherapy studies published [20, 21] , the combination of cisplatin and etoposide is recommended as first-line therapy for metastatic NEC [1] . Due to less toxic effect and less dependence on renal function, cisplatin has been replaced by carboplatin in advanced ovarian cancer and extensive small-cell lung cancer, but not in testicular cancer where carboplatin was found to be inferior to cisplatin [29] [30] [31] . Our study indicates that in GI-NEC, cisplatin could probably be replaced by carboplatin, as the two compounds were comparable in efficacy regarding the response rates, PFS and survival. After first-line treatment, no further standard therapy has yet been established in GI-NEC. Our data indicate that retreatment with platinum/etoposide is an option, as 42% had a re-stabilization of the disease. There is no established second-line chemotherapy treatment, although a recent report shows effect of temozolomide/capecitabine [12] . In our study, 100 patients received second-line treatment and 51% had disease stabilization, indicating that many GI-NEC patients will benefit from further lines of chemotherapy. It is increasingly recognized that variations in outcome in cancer patients are not solely determined by the characteristics of the tumor, but also by host-response factors. In our study, we found that several laboratory abnormalities correlated with poor survival, with LDH and platelet count as the strongest factors. There are limited data why these abnormal laboratory values evolve and what they reflect [22] . Recent data suggest that LDH is a biomarker for hypoxia and highly angiogenetic tumors, and high LDH-5 is directly related to an up-regulated HIF pathway and linked with an aggressive tumor phenotype [32, 33] . Markers of a systemic host inflammatory response, elevated platelets and leucocytes, have been shown to have a prognostic value in a variety of common solid tumors [34] .
In summary, advanced GI-NEC patients have a poor prognosis and should be considered for chemotherapy treatment without delay. Poor PS, colorectal primary and elevated platelets and LDH levels were the most important negative prognostic factors for survival in this large retrospective study. GI-NEC patients with Ki-67 < 55% are less responsive to platinum-based chemotherapy, but have a longer survival than patients with a higher Ki-67. Our data indicate that it might not be correct to consider all GI-NEC as one single disease entity as in the present WHO classification. Additional clinical and molecular tumor data are needed to define possible subgroups within the GI-NEC classification in order to individualize future treatment of these patients.
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